Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer

International Journal of Urology

Volumn 4, Issue 1, 1997, Pages 74-78

  Tsutsumi, Masakazu ^a   Sugano, Kokichi ^b   Yamaguchi, Kensei ^c   Kakizoe, Tadao ^b   Akaza, Hideyuki ^d  

^a Ibaraki University   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Self Defense Forces Central Hospital   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bladder cancer; Loss of heterozygosity (LOH); Malignant progression; P53 gene; PCR SSCP analysis; Prognostic factor

Indexed keywords

DNA; FORMALDEHYDE; PARAFFIN;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DISEASE COURSE; GENE LOCUS; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0030892417     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1997.tb00144.x     Document Type: Article

References (28)

1. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA. Mechanism of activation of human oncogene. Nature 1982;300:143-149.
2. Reddy EP, Eynold RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T-24 human bladder carcinoma oncogene. Nature 1982;300:149-152.
3. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 1994;151:545-560.
4. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
5. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393-1398.
6. Uchida T, Wada C, Ishida H, Wang C, Egawa S, Yokoyama E, Kameya T, Koshiba K. p53 mutations and prognosis in bladder tumors. J Urol 1995; 153:1097-1104.
7. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Jones PA. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788.
8. Akaza H, Koiso K, Kotake T, Matsumura Y, Isaka S, Machisa T, Obata Y, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Kagawa S, Niijima T. Long term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 1992;30(suppl):s 15-20.
9. Levi S, Urbano-Ispizua S, Gill R, Thomas DM, Gilbetson J, Foster C. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991;51:3497-3502.
10. Yamaguchi K, Sugano K, Kyogoku A, Nakashima Y, Saotome K, Yokoyama T, Yokota T, Ohkura H. PCR-base approaches for detection of allelic loss in the p53 tumor suppresser gene in colon neoplasms. Am J Gastroenterol (in press).
11. Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Iseri O, Vogelstein B, Resau JH. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci USA 1991;88:4976-4980.
12. Ito T, Seyama T, Hayashi T, Mizuno T, Iwamoto KS, Tsuyama N, Doi K, Nakamura N, Akiyama M. Hae III polymorphism in intron 1 of the human P53 gene. Hum Genet 1994;93:222.
13. Sugano K, Nakashima Y, Yamaguchi K, Fukayama N, Mackawa M, Ohkuma H, Kakizoe T, Sekiya T. Sensitive detection by fluorescence-base single-strand conformation polymorphism analysis using blunt-end DNA fragment. Genes Chromosomes Cancer 1996; 15:157-164.
14. Sugano K, Kyogoku A, Fukayama N, Ohkura H, Shimosato Y, Sekiya T, Hayashi K. Rapid and simple detection of c-Ki-ras2 gene codon 12 mutations by nonradioisotopic single strand conformation polymorphism analysis. Lab Invest 1993;68:361-366.
15. Hosmmer DW, Lemeshaw S. Applied Logistic Regression. New York: Wiley, 1989.
16. Sossui T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-952.
17. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-1011.
18. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
19. Nakapoulou L, Constantinides C, Papandropoulos J, Thedororopoulos G, Tsonou DMScA, Giannoupoulos A, Zervas A, Dimopoulos C. Evaluation of overexpression of p53 tumor suppresser protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 1995;46:334-340.
20. Sarkis AS, Bajorin DF, Victor E, Herr HW, Netto G, Zhang Z-F, Schultsz PK, Cordon-Cardo C, Scher HI. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-1390.
21. Raghavan D, Shipley WU, Garnik MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990;322:1129-1138.
22. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-64.
23. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-59.
24. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ, Lavin MF. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumor progression. Br J Urol 1994;73:526-532.
25. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-370.
26. Prioleasu J, Schnitt SJ. p53 antigen loss in stored paraffin slides. N Engl J Med 1995;332:1521-1522.
27. Sidransky D, Frost P, Eschenback AV, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326:737-740.
28. Habuchi T, Takahashi R, Yamada H, Kakei Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087-1088.